Cygnal Therapeutics
Noubar Afeyan is a founding chairman at Cygnal Therapeutics. Noubar has also previously worked with ProFound Therapeutics, Alltrna, Generate Biomedicines, Inc., Tessera Therapeutics, and the Massachusetts Institute of Technology (MIT). In addition, Noubar has also been a part of Omega Therapeutics, Rubius Therapeutics, Moderna Therapeutics, and Flagship Pioneering.
Noubar Afeyan received their PhD in Biochemical Engineering from the Massachusetts Institute of Technology and their BS in Chemical Engineering from McGill University.
This person is not in the org chart
This person is not in any teams
Cygnal Therapeutics
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology.